| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1
* Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA, and
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
1Correspondence: 986025 Nebraska Medical Center, Omaha, NE 68198-6025, USA. E-mail: vlabhase{at}unmc.edu
The endo-lysosomal escape of drug carriers is crucial to enhancing the efficacy of their macromolecular payload, especially the payloads that are susceptible to lysosomal degradation. Current vectors that enable the endo-lysosomal escape of macromolecules such as DNA are limited by their toxicity and by their ability to carry only limited classes of therapeutic agents. In this paper, we report the rapid (<10 min) endo-lysosomal escape of biodegradable nanoparticles (NPs) formulated from the copolymers of poly(DL-lactide-co-glycolide) (PLGA). The mechanism of rapid escape is by selective reversal of the surface charge of NPs (from anionic to cationic) in the acidic endo-lysosomal compartment, which causes the NPs to interact with the endo-lysosomal membrane and escape into the cytosol. PLGA NPs are able to deliver a variety of therapeutic agents, including macromolecules such as DNA and low molecular weight drugs such as dexamethasone, intracellularly at a slow rate, which results in a sustained therapeutic effect. PLGA has a number of advantages over other polymers used in drug and gene delivery including biodegradability, biocompatibility, and approval for human use granted by the U.S. Food and Drug Administration. Hence PLGA is well suited for sustained intracellular delivery of macromolecules.—Panyam, J., Zhou, W. Z., Prabha, S., Sahoo, S. K., Labhasetwar, V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery.
Key Words: intracellular delivery • gene therapy • antiproliferative effect • sustained release • restenosis
This article has been cited by other articles:
|
|
 |
|
  S. Kimura, K. Egashira, K. Nakano, E. Iwata, M. Miyagawa, H. Tsujimoto, K. Hara, Y. Kawashima, R. Tominaga, and K. Sunagawa Local Delivery of Imatinib Mesylate (STI571)-Incorporated Nanoparticle Ex Vivo Suppresses Vein Graft Neointima Formation Circulation, September 30, 2008; 118(14_suppl_1): S65 - S70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Colognato, A. Bonelli, J. Ponti, M. Farina, E. Bergamaschi, E. Sabbioni, and L. Migliore Comparative genotoxicity of cobalt nanoparticles and ions on human peripheral leukocytes in vitro Mutagenesis, September 1, 2008; 23(5): 377 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-P. Guan, D.-P. Quan, K.-R. Liao, Tao Wang, Peng Xiang, and K.-C. Mai Preparation and Characterization of Cationic Chitosan-modified Poly(D,L-lactide-co-glycolide) Copolymer Nanospheres as DNA Carriers J Biomater Appl, January 1, 2008; 22(4): 353 - 371. [Abstract] [PDF]
|
|
|
|
 |
|
 J. K. Vasir and V. Labhasetwar Preparation of Biodegradable Nanoparticles and Their Use in Transfection CSH Protocols, January 1, 2008; 2008(2): pdb.prot4888 - pdb.prot4888. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Lu, Q. Sun, J. Wan, Z. She, and X.-G. Jiang Cationic Albumin-Conjugated Pegylated Nanoparticles Allow Gene Delivery into Brain Tumors via Intravenous Administration Cancer Res., December 15, 2006; 66(24): 11878 - 11887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Moghimi, A. C. Hunter, and J. C. Murray Nanomedicine: current status and future prospects FASEB J, March 1, 2005; 19(3): 311 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Muro, X. Cui, C. Gajewski, J.-C. Murciano, V. R. Muzykantov, and M. Koval Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress Am J Physiol Cell Physiol, November 1, 2003; 285(5): C1339 - C1347. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
